Kirn David sold $811K of FDMT
Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $13.90 ($0.81M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale represents a modest reduction in insider ownership, which may be interpreted as a slight bearish signal.
Market read
Primary source insider sale; modest materiality for a micro‑cap biotech.
What to watch
The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.
Background
Form 4 filings disclose insider transactions; investors monitor them for potential signals.
Ticker impact
Officer/director Kirn David sold 58,333 shares of 4D Molecular Therapeutics for $811,004 on Sep 14, 2026.
Possible short-term downward pressure on FDMT as the market digests the insider sell.
A $811k sale by an officer is material for a micro‑cap biotech; such sales often precede price weakness, but the impact may be limited.
Market effects
Minimal; biotech sector may view the sale as a routine insider transaction.
None
Low
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- Officer/DirectorKirn David
Insider who sold shares under a 10b5-1 plan.
- Company4D Molecular Therapeutics, Inc.
Biotech firm listed under ticker FDMT.
